上海国资出手！300841，提前暴涨16%，今日复牌

Core Viewpoint - Kanghua Biotech's controlling shareholder will change to Wankexin Biotech, leading to a significant stock price increase of 16.2% prior to the announcement [1][4]. Group 1: Shareholder Change - Kanghua Biotech announced on July 20 that its controlling shareholder will be transferred to Shanghai Wankexin Biotech, with a total of 28.4666 million shares, accounting for 21.91% of the total share capital, being sold at approximately 65.03 yuan per share, totaling about 1.851 billion yuan [4][5]. - After the transfer, Wankexin Biotech will hold 29.99% of the voting rights in Kanghua Biotech, while the previous controlling shareholder, Wang Zhentao, will retain 8.08% of the shares but delegate voting rights to Wankexin Biotech [4][5]. Group 2: Financial Commitments - Wang Zhentao and Aokang Group have committed that the net profit attributable to the parent company, after deducting non-recurring gains and losses, will not be less than 728 million yuan for the years 2025 to 2026, with R&D expenses not less than 260 million yuan [6]. Group 3: Wankexin Biotech Structure - Wankexin Biotech was established on July 8, 2025, with a total capital contribution of 763 million yuan, where the main controlling entity is Shanghai Shenshi Pharmaceutical Management Consulting Co., which holds 0.001% of the partnership shares [8][12]. - The Shanghai Biopharmaceutical M&A Fund holds 80.209% of the partnership shares in Wankexin Biotech, indicating significant involvement from this fund in the transaction [8][10]. Group 4: Background of Partners - The partners of Lubu Ka, which is involved in Wankexin Biotech, include individuals with significant roles in the Shanghai Biopharmaceutical M&A Fund, suggesting potential overlaps in management and strategic direction [12][16]. - Key figures such as Jiang Junhang and Liu Dawei have held prominent positions in both Wankexin Biotech and the Shanghai Biopharmaceutical M&A Fund, indicating a strong connection between the two entities [16].